BR112023017099A2 - Anticorpos que se ligam a cd123 e a receptores de células t gama-delta - Google Patents
Anticorpos que se ligam a cd123 e a receptores de células t gama-deltaInfo
- Publication number
- BR112023017099A2 BR112023017099A2 BR112023017099A BR112023017099A BR112023017099A2 BR 112023017099 A2 BR112023017099 A2 BR 112023017099A2 BR 112023017099 A BR112023017099 A BR 112023017099A BR 112023017099 A BR112023017099 A BR 112023017099A BR 112023017099 A2 BR112023017099 A2 BR 112023017099A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- bind
- delta
- gamma
- cell receptors
- Prior art date
Links
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 title abstract 2
- 102000011778 gamma-delta T-Cell Antigen Receptors Human genes 0.000 title abstract 2
- 108010062214 gamma-delta T-Cell Antigen Receptors Proteins 0.000 title abstract 2
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 102000052088 human IL3RA Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
anticorpos que se ligam a cd123 e a receptores de células t gama-delta. a presente invenção refere-se a anticorpos que têm capacidade de ligação a cd123 humano e que têm capacidade de ligação à cadeia vd2 de um receptor de células t de v?9vd2 humana. a invenção refere-se ainda a composições farmacêuticas que compreendem os anticorpos da invenção e a usos dos anticorpos da presente invenção para tratamento médico.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21159698 | 2021-02-26 | ||
US202163166339P | 2021-03-26 | 2021-03-26 | |
US202163274709P | 2021-11-02 | 2021-11-02 | |
EP21211114 | 2021-11-29 | ||
PCT/EP2022/054993 WO2022180271A1 (en) | 2021-02-26 | 2022-02-28 | Antibodies that bind CD123 and gamma-delta T cell receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023017099A2 true BR112023017099A2 (pt) | 2023-11-21 |
Family
ID=80786427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023017099A BR112023017099A2 (pt) | 2021-02-26 | 2022-02-28 | Anticorpos que se ligam a cd123 e a receptores de células t gama-delta |
Country Status (9)
Country | Link |
---|---|
US (1) | US20240141071A1 (pt) |
EP (1) | EP4298125A1 (pt) |
JP (1) | JP2024507937A (pt) |
KR (1) | KR20230169950A (pt) |
AU (1) | AU2022225091A1 (pt) |
BR (1) | BR112023017099A2 (pt) |
CA (1) | CA3209454A1 (pt) |
MX (1) | MX2023009950A (pt) |
WO (1) | WO2022180271A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4292610A1 (en) * | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Variant antibodies that bind gamma-delta t cell receptors |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
FR2879605B1 (fr) | 2004-12-16 | 2008-10-17 | Centre Nat Rech Scient Cnrse | Production de formats d'anticorps et applications immunologiques de ces formats |
AU2006317242A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
WO2010059315A1 (en) | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
WO2010111625A1 (en) | 2009-03-27 | 2010-09-30 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
JP5997154B2 (ja) | 2010-08-16 | 2016-09-28 | ノビミューン エスアー | 多重特異性多価抗体の生成方法 |
PT2838917T (pt) | 2012-04-20 | 2019-09-12 | Merus Nv | Métodos e meios para a produção de moléculas similares a ig heterodiméricas |
WO2014081202A1 (ko) | 2012-11-21 | 2014-05-30 | 주식회사 파멥신 | Vegfr-2와 dll4를 표적으로 하는 이중표적항체 및 이를 포함하는 약학적 조성물 |
JP6617138B2 (ja) | 2014-04-10 | 2019-12-11 | ラヴァ・セラピューティクス・ベー・フェー | ヒトVγ9Vδ2 T細胞受容体と結合する免疫グロブリン |
EP3853256A1 (en) | 2018-09-19 | 2021-07-28 | Lava Therapeutics B.V. | Dual acting cd1d immunoglobulin |
CN114040926A (zh) * | 2019-05-04 | 2022-02-11 | 印希比股份有限公司 | 结合cd123的多肽及其用途 |
BR112021022089A2 (pt) | 2019-05-08 | 2022-02-08 | Janssen Biotech Inc | Materiais e métodos para modulação da imunidade mediada por células t |
-
2022
- 2022-02-28 WO PCT/EP2022/054993 patent/WO2022180271A1/en active Application Filing
- 2022-02-28 BR BR112023017099A patent/BR112023017099A2/pt unknown
- 2022-02-28 JP JP2023551762A patent/JP2024507937A/ja active Pending
- 2022-02-28 AU AU2022225091A patent/AU2022225091A1/en active Pending
- 2022-02-28 MX MX2023009950A patent/MX2023009950A/es unknown
- 2022-02-28 KR KR1020237032819A patent/KR20230169950A/ko unknown
- 2022-02-28 US US18/278,956 patent/US20240141071A1/en active Pending
- 2022-02-28 CA CA3209454A patent/CA3209454A1/en active Pending
- 2022-02-28 EP EP22708159.3A patent/EP4298125A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4298125A1 (en) | 2024-01-03 |
AU2022225091A1 (en) | 2023-09-07 |
WO2022180271A1 (en) | 2022-09-01 |
JP2024507937A (ja) | 2024-02-21 |
US20240141071A1 (en) | 2024-05-02 |
MX2023009950A (es) | 2023-11-10 |
KR20230169950A (ko) | 2023-12-18 |
CA3209454A1 (en) | 2022-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018012794A2 (pt) | receptor de célula t, tcr que se liga a um complexo hla-a*02 sllmwitqc, fusão anti-cd3 de tcr, ácido nucléico, vetor de expressão, célula que ocorre e/ou purificada e/ou concebida de maneira não natural, célula, composição farmacêutica, método de tratamento de um indivíduo humano, formulação injetável para administração a um indivíduo humano, e método de produção de uma tcr | |
BR112022021322A2 (pt) | Anticorpo contra nectina-4 e aplicação do mesmo | |
BR112022011749A2 (pt) | Anticorpos anti-ccr8 e seus usos | |
BR112017026189A2 (pt) | tratamento de câncer através do bloqueio combinado das vias de sinalização de pd-1 e cxcr4 | |
BR112018067522A2 (pt) | anticorpos específicos para receptor de poliovírus humano (pvr) | |
BR112021015238A8 (pt) | Novos anticorpos de ligação a cd40 | |
BR112023017099A2 (pt) | Anticorpos que se ligam a cd123 e a receptores de células t gama-delta | |
UY31466A1 (es) | Anticuerpos monoclonales que se unen al hgm-csf y las composiciones médicas que los comprenden | |
BR112022003589A2 (pt) | Conjugado de anticorpo-fármaco compreendendo anticorpo contra ror1 humano e uso para o mesmo | |
BR112022018088A2 (pt) | Novos anticorpos anti-lilrb4 e produtos derivados | |
BR112021014074A2 (pt) | Proteínas de ligação ao antígeno anti-receptor il2 gama | |
BR112019010595A2 (pt) | anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto. | |
BR112022015416A2 (pt) | Anticorpos anti-ror1 e composições | |
BR112016020871A2 (pt) | anticorpos anti-mcam e métodos associados de uso | |
BR112022021690A2 (pt) | Anticorpos de cadeia pesada multispecíficos com regiões constantes de cadeia pesada modificadas | |
BR112018002436A2 (pt) | tratamento de combinação de usos de métodos destes | |
AR083937A1 (es) | Proteinas de union a antigenos | |
AR119346A1 (es) | Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados | |
BR112021019107A2 (pt) | Anticorpos contra amiloide-beta piroglutamato e usos dos mesmos | |
UY37598A (es) | Anticuerpos miméticos de fgf21 y usos de los mismos | |
CO2022002573A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
BR112023019749A2 (pt) | Conjugados de exatecano anti-nectina-4, composição farmacêutica que os compreende e seus usos | |
BR112022009510A2 (pt) | Análogo de insulina, composição farmacêutica, e, método de tratamento, prevenção ou alívio de uma doença ou distúrbio ou condição | |
UY38520A (es) | Anticuerpos anti-pmel17, sus conjugados, composiciones que los comprenden, polinucleótidos, métodos y usos relacionados a los mismos | |
BR112023000515A2 (pt) | Composição farmacêutica e seu uso |